CYTTHERAPEUTICS INC. overview

SOUTH SAN FRANCISCO, Calif., Feb. 02, 2017 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, today announced that the company’s management will participate in two upcoming investor conferences. Bob Goeltz, chief financial officer, will participate in a company fireside chat at the 6th Annual LEERINK Partners Global Healthcare Conference on Thursday, February 16, 2017, at 1:00...

SOUTH SAN FRANCISCO, Calif., Feb. 02, 2017 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, today announced the treatment of the first patient in the PROCLAIM ( Pro body Cl inical A ssessment I n M an) CX-072 study, a Phase 1/2 clinical trial evaluating CX-072, a PD-L1-targeting Probody therapeutic, as monotherapy and in combination with Yervoy ® (ipilimumab) or Zelboraf ®...